Genetic and molecular characterization of uveal melanoma cell lines

Pigment Cell and Melanoma Research

Volumn 25, Issue 2, 2012, Pages 182-187

  Griewank, K G ^a   Yu, X ^b   Khalili, J ^b   Sozen, M M ^a   Stempke Hale, K ^b   Bernatchez, C ^b   Wardell, S ^b   Bastian, B C ^c   Woodman, S E ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GNA11; GNAQ; Uveal melanoma

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S 100; TYROSINASE RELATED PROTEIN 1;

ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA FINGERPRINTING; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; MELANOMA CELL; UVEA MELANOMA;

EID: 84857444671     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.00971.x     Document Type: Article

References (31)

1. Ballou, L.M., Lin, H.Y., Fan, G., Jiang, Y.P., and Lin, R.Z. (2003). Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 278, 23472-23479.
2. Ballou, L.M., Chattopadhyay, M., Li, Y., Scarlata, S., and Lin, R.Z. (2006). Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem. J. 394, 557-562.
3. Bedikian, A.Y. (2006). Metastatic uveal melanoma therapy: current options. Int. Ophthalmol. Clin. 46, 151-166.
4. Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F.D.R., Eychã̈Ne, A., and Mascarelli, F.D.R. (2003). Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 278, 42409-42418.
5. Chatterjee, R. (2007). Cases of mistaken identity. Science 315, 928-931.
6. Cohen, Y., Goldenberg-Cohen, N., Parrella, P., Chowers, I., Merbs, S.L., Pe’Er, J., and Sidransky, D. (2003). Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44, 2876-2878.
7. De Waard-Siebinga, I., Blom, D.J., Griffioen, M., Schrier, P.I., Hoogendoorn, E., Beverstock, G., Danen, E.H., and Jager, M.J. (1995). Establishment and characterization of an uveal-melanoma cell line. Int. J. Cancer 62, 155-161.
8. Edmunds, S.C., Cree, I.A., Di Nicolantonio, F., Hungerford, J.L., Hurren, J.S., and Kelsell, D.P. (2003). Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 88, 1403-1405.
9. Folberg, R., Kadkol, S.S., Frenkel, S., Valyi-Nagy, K., Jager, M.J., Pe'er, J., and Maniotis, A.J. (2008). Authenticating cell lines in ophthalmic research laboratories. Invest. Ophthalmol. Vis. Sci. 49, 4697-4701.
10. Henriquez, F., Janssen, C., Kemp, E.G., and Roberts, F. (2007). The T1799A BRAF mutation is present in iris melanoma. Invest. Ophthalmol. Vis. Sci. 48, 4897-4900.
11. Howes, A.L., Arthur, J.F., Zhang, T., Miyamoto, S., Adams, J.W., Dorn Ii, G.W., Woodcock, E.A., and Brown, J.H. (2003). Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4, 5-bisphosphate depletion. J. Biol. Chem. 278, 40343-40351.
12. Janakiraman, M., Vakiani, E., Zeng, Z. et al. (2010). Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901-5911.
13. Janssen, C.S., Sibbett, R., Henriquez, F.L., Mckay, I.C., Kemp, E.G., and Roberts, F. (2008). The T1799A point mutation is present in posterior uveal melanoma. Br. J. Cancer 99, 1673-1677.
14. Kan-Mitchell, J., Mitchell, M.S., Rao, N., and Liggett, P.E. (1989). Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest. Ophthalmol. Vis. Sci. 30, 829-834.
15. Ko, J.M., Velez, N.F., and Tsao, H. (2010). Pathways to melanoma. Semin. Cutan. Med. Surg. 29, 210-217.
16. Lacroix, M. (2008). Persistent use of "false" cell lines. Int. J. Cancer 122, 1-4.
17. Lefevre, G.L., Glotin, A.-L., Calipel, A., Mouriaux, F.D.R., Tran, T., Kherrouche, Z., Maurage, C.-A., Auclair, C., and Mascarelli, F.D.R. (2004). Roles of stem cell factor/c-Kit and effects of Glivec®/STI571 in human uveal melanoma cell tumorigenesis. J. Biol. Chem. 279, 31769-31779.
18. Luyten, G.P., Naus, N.C., Mooy, C.M., Hagemeijer, A., Kan-Mitchell, J., Van Drunen, E., Vuzevski, V., De Jong, P.T., and Luider, T.M. (1996). Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int. J. Cancer 66, 380-387.
19. Maat, W., Kilic, E., Luyten, G.P.M., De Klein, A., Jager, M.J., Gruis, N.A., and Van Der Velden, P.A. (2008). Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 23-27.
20. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M.G., Pe'er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J.C. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752.
21. Nareyeck, G., Zeschnigk, M., Bornfeld, N., and Anastassiou, G. (2009). Novel cell lines derived by long-term culture of primary uveal melanomas. Ophthalmologica 223, 196-201.
22. Populo, H., Soares, P., Rocha, A.S., Silva, P., and Lopes, J.M. (2010). Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 20, 107-117.
23. Rummelt, V., Mehaffey, M.G., Campbell, R.J., Pe'er, J., Bentler, S.E., Woolson, R.F., Naumann, G.O.H., and Folberg, R. (1998). Microcirculation architecture of metastases from primary ciliary body and choroidal melanomas. Am. J. Ophthalmol. 126, 303-305.
24. Saraiva, V.S., Caissie, A.L., Segal, L., Edelstein, C., and Burnier, Jr, M.N. (2005). Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res. 15, 245-250.
25. Singh, A.D., Turell, M.E., and Topham, A.K. (2011). Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118, 1881-1885.
26. Soulieres, D., Rousseau, A., Deschenes, J., Tremblay, M., Tardif, M., and Pelletier, G. (1991). Characterization of gangliosides in human uveal melanoma cells. Int. J. Cancer 49, 498-503.
27. Van Dinten, L.C., Pul, N., Van Nieuwpoort, A.F., Out, C.J., Jager, M.J., and Van Den Elsen, P.J. (2005). Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest. Ophthalmol. Vis. Sci. 46, 24-30.
28. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O/'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
29. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2011). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
30. Weber, A., Hengge, U.R., Urbanik, D., Markwart, A., Mirmohammadsaegh, A., Reichel, M.B., Wittekind, C., Wiedemann, P., and Tannapfel, A. (2003). Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab. Invest. 83, 1771-1776.
31. Zuidervaart, W., Van Nieuwpoort, F., Stark, M. et al. (2005). Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br. J. Cancer 92, 2032-2038.